Emergent BioSolutions Inc.
- Jurisdiction
United States - LEI
549300YW6TUOX8BE5103 - ISIN
US29089Q1058 (EBS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Read full profile
Fundamentals
- Net revenue
€721.77M - Gross margin
49.1% - EBIT
€90.84M - EBIT margin
12.6% - Net income
€118.99M - Net margin
16.5%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
| N/A | N/A |
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Zoon Kathryn C | N/A |
|
|
|
|
| DeGolyer Donald W | N/A |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Steve Cohen | January 10, 2025 | $1.00K–$15.00K |
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 1, 2024 (Q1 2024)